Insider Analysis From Kantar Health On Improving Compliance In China’s Diabetes Patients
This article was originally published in PharmAsia News
Executive Summary
China is expected to see the level of diabetes among its population rise by nearly two-thirds over the next few decades, and the majority of Chinese patients do not take their medication as directed. Pharma companies can help educate consumers to improve compliance and better manage the disease.